-
Health todayObesity, diabetes and GLP-1 confirms
GLP-1 receptor agonists do not improve cognition or function in Alzheimer's disease or MCI
GLP-1 receptor agonists improved neither cognition nor disease progression in pooled trials, with more adverse events and discontinuation.
Peer-reviewed -
Data, models and systemsForecasts and their record new
US obesity treatment access modelled as 5.3 million preventable deaths over a decade
Modelling projects 5.3 million preventable deaths and $10.5-13.3 trillion foregone benefits over a decade of restricted obesity treatment access.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
GLP-1 agonists and atrial fibrillation in non-diabetic obesity with kidney disease
GLP-1 users with obesity and CKD had 1.63% one-year incident atrial fibrillation, against 2.62% in unexposed patients.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
Type 2 diabetes remission is uncommon, brief and usually ended by a treatment restart
Recorded remission reached 3.82% at five years in treated adults, and ended more often by treatment restart than rising HbA1c.
Preprint · not peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
Type 2 diabetes being diagnosed at older ages in Israel, and with more co-morbidities
Median age at diagnosis rose from 63.0 to 66.7 years between 2005-2008 and 2020-2023 in one Israeli health system.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
Tirzepatide price rise shifted UK self-paying patients to semaglutide
Among 1,033,522 UK adults self-funding GLP-1 treatment, semaglutide initiation rose 31 percentage points in the month tirzepatide's list price rose.
Peer-reviewed -
Data, models and systemsValue in health new
NHS online diabetes self-management service modelled at £13,192 per QALY
A patient-level simulation of an NHS online service for type 2 diabetes estimated a gain of 0.016 QALYs and a net cost of £216 per user.
Peer-reviewed -
Health todayHeart and stroke refines
Tirzepatide versus dulaglutide in type 2 diabetes, by heart failure status
Tirzepatide gave a hazard ratio of 0.83 for all-cause death or heart failure events in those with prior heart failure.
Peer-reviewed -
Tomorrow's worldInnovation in treatment new
BCG immunotherapy lowers HbA1c for up to eight years in long-standing type 1 diabetes
HbA1c fell 7.04% from baseline at year 5 and 12.84% at year 8 with BCG, unchanged on placebo.
Preprint · not peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
Adding nutrition therapy to tirzepatide tracked with 19.7% weight loss against 15.6%
In a telemedicine obesity programme of 4,269 adults, GLP-1-naive tirzepatide users given individualised carbohydrate-reduced nutrition therapy lost 19.7% of body weight at 12 months, as compared to 15.6% without it.
Preprint · not peer-reviewed -
Behavioural scienceAdherence and persistence new
Most adults starting semaglutide or tirzepatide did not continue for a year
Among 743,153 US adults starting semaglutide or tirzepatide for obesity in 2024, 29.9% and 35.9% respectively were still being prescribed the drug at 12 months.
Preprint · not peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
Oral safiglipron lowered HbA1c as much as dapagliflozin, and more at 90 mg
In adults with type 2 diabetes, once-daily oral safiglipron lowered HbA1c at least as much as dapagliflozin, and by more at the 90 mg dose.
Peer-reviewed